Regeneron Pharmaceuticals Stock May Be Worth Buying Again – Rating Upgrade

view original post

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for my updated look at REGN.